牛熊異動 | 新藥獲許可,復星醫藥購漲超35%
復星醫藥宣佈,近日,公司控股子公司復星醫藥產業收到國家藥品監督管理局關於同意其獲許可的RT002(“該新藥”)用於中 重度眉間紋治療開展臨牀試驗的通知書。復星醫藥產業擬於近期條件具備後於中國境內(不包括港澳臺地區)開展該新藥的III期臨牀試驗。復星醫藥產業於2018年12月獲美國Revance關於該新藥在區域內(即中國大陸、香港及澳門特區)獨家使用、進口、銷售及其他商業化(不包括製造)的權 利許可,Revance仍爲該新藥在區域內的權利人。該新藥爲生物製品,擬用於(1)美容適應症,如治療中重度眉間紋;以及(2)治療適應症,如頸部肌張力障礙。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.